Advertisement
Advertisement
U.S. markets close in 57 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Atara Biotherapeutics, Inc. (ATRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4250-0.3150 (-6.65%)
As of 03:03PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.7400
Open4.5900
Bid4.4400 x 1800
Ask4.4500 x 1800
Day's Range4.4200 - 4.7000
52 Week Range2.8300 - 20.0400
Volume819,006
Avg. Volume2,436,946
Market Cap417.553M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Atara Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Business Wire

    Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update

    SOUTH SAN FRANCISCO, Calif., August 08, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2022, an update to its corporate strategy, recent business highlights, and key upcoming catalysts.

  • Business Wire

    Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., August 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 82,756 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 98,701 shares of Atara’s common stock to two such newly hired em

  • Business Wire

    Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

    SOUTH SAN FRANCISCO, Calif., August 03, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.

Advertisement
Advertisement